Table 2.
Characteristics of patients at start of ETNa who had a clinical visit within 30 days, by JIA categoryb (ETN Initiator Cohort, n = 443)
| PersistOligod | ExtOligoe | RF + pJIAf | RF-pJIAg | ERAh | Psoriaticii | SJIAj | Undiffk | |
|---|---|---|---|---|---|---|---|---|
| Number of patientsc | 53 | 30 | 64 | 192 | 57 | 33 | 3 | 11 |
| Age at diagnosis in years, median (IQR) | 5.0 (2.0, 10.0) | 5.0 (3.0, 8.5) | 13.0 (10.0, 15.0) | 10.0 (5.0, 13.0) | 11.0 (9.0, 14.0) | 9.0 (2.0, 14.0) | 6.0 (3.0, 17.0) | 14.0 (11.0, 15.0) |
| Activel enthesitis (%)l | 3.8 | 10.0 | 6.3 | 7.8 | 56.1 | 24.2 | 0 | 18.2 |
| Active sacroiliitis (%) | 0 | 3.3 | 1.6 | 2.1 | 36.8 | 12.1 | 0 | 18.2 |
| Active joint count, median (IQR) | 1.5 (1.0, 2.0) | 3.5 (1.0, 6.0) | 7.5 (5.0, 16.5) | 6.0 (3.0, 14.0) | 3.0 (1.0, 9.0) | 5.0 (2.0, 8.0) | 2.0 (1.0, 20.0) | 4.0 (3.0, 12.0) |
| Prior steroid injection (%) | 67.9 | 73.3 | 15.6 | 22.4 | 17.5 | 18.2 | 0 | 27.3 |
| Hxm of 1 DMARDn,o (%) | 75.5 | 84.0 | 50.8 | 60.0 | 48.2 | 51.5 | 0 | 54.5 |
| Any MTXp (%) | 75.5 | 80.0 | 50.8 | 58.9 | 44.6 | 45.5 | 0 | 27.3 |
| Hx of > 1 DMARD (%) | 5.7 | 12.0 | 3.3 | 3.8 | 7.1 | 6.1 | 0 | 0 |
| 1 biologic prior to ETN (%) | 1.9 | 6.9 | 3.1 | 6.3 | 7.0 | 9.1 | 0 | 0 |
| No concurrent DMARD with ETN (%) | 24.5 | 26.9 (7/26) | 9.7 (6/62) | 16.0 (30/187) | 42.9 | 30.3 | 66.7 | 36.4 |
| DMARD for ≤3 months after ETN start (%) | 41.5 | 38.5 (10/26) | 24.6 (15/61) | 21.5 (40/186) | 16.1 | 24.2 | 33.3 | 18.2 |
| DMARD for > 3 months after ETN start (%) | 34.0 | 36.0 (9/25) | 67.7 (42/62) | 64.5 (120/186) | 41.1 | 45.5 | 0 | 54.5 |
| CHAQq, Median (IQR) | 0.1 (0.0, 0.6) | 0.4 (0.0, 0.8) | 1.1 (0.4, 1.5) | 0.6 (0.1, 1.3) | 0.5 (0.3, 0.9) | 0.6 (0.3, 1.1) | 0.5 (0.1, 0.9) | 0.7 (0.3, 1.0) |
| cJADASr Median (IQR) | 7.0 (4.5, 11.0) | 11.0 (7.5, 15.0) | 18.5 (12.0, 22.0) | 15.0 (9.3, 20.0) | 11.5 (7.8, 16.0) | 13.0 (8.0, 17.0) | 11.5 (11.5, 11.5) | 11.0 (7.5, 14.0) |
| Physician Global Median (IQR) | 3.0 (2.0, 4.0) | 3.0 (2.0, 4.0) | 5.0 (3.0, 7.5) | 4.0 (2.8, 6.0) | 3.0 (2.0, 5.0) | 4.0 (2.0, 5.0) | 5.0 (3.5, 6.5) | 3.0 (2.0, 5.0) |
| Patient Global, Median (IQR) | 2.5 (0.0, 5.0) | 3.0 (1.0, 5.0) | 5.0 (3.0, 7.0) | 4.0 (2.0, 6.0) | 4.0 (2.0, 6.0) | 3.0 (2.0, 6.0) | 6.5 (6.0, 7.0) | 2.0 (1.0, 5.0) |
| Pains, Median (IQR) | 2.5 (0.0, 6.0) | 4.5 (2.0, 6.0) | 5.0 (3.0, 7.0) | 4.0 (2.0, 6.0) | 5.0 (3.0, 7.0) | 4.0 (1.0, 5.0) | 5.5 (4.0, 7.0) | 5.0 (3.0, 6.0) |
aETN etanercept; b excludes oligoarticular JIA with unknown course; c percentages indicate percent of ILAR category, percentages were calculated for available n for each row, JIA category was determined at ETN initiation (prior to or up to 30 days after or closest visit to initiation);dPersistOligo persistent oligoarticular JIA, eExtOligo extended oligoarticular JIA, fRF + pJIA polyarticular rheumatoid factor positive JIA, gRF–pJIA polyarticular rheumatoid factor negative JIA, hERA enthesitis related arthritis, iPsoriatic psoriatic JIA, jSJIA systemic JIA, kUndiff undifferentiated JIA, lactive clinically active, mHx history at any time > 1 month prior to starting ETN, nDMARD non-biologic disease modifying anti-rheumatic drug; o medication data was not usable in certain cases, therefore the total of the three categories may add up to > 100%, denominators are provided for JIA categories in which this occurred, pMTX methotrexate, qCHAQ Childhood Health Assessment Questionnaire, rcJADAS10 clinical juvenile arthritis activity score (10 joints); s measured by a Likert scale from 0 (no pain) to 10 (worst pain)